MMRF Showcases CoMMpass StudySM at Upcoming American Society of Hematology Annual Meeting

MMRF Showcases CoMMpass StudySM at Upcoming American Society of Hematology Annual Meeting

The Multiple Myeloma Research Foundation (MMRF) announced that 34 abstracts will be presented at the 61st American Society of Hematology Annual Meeting in Orlando from December 7-10. The presence of the highly influential MMRF study called the CoMMpass StudySM, representing the largest genomic data set of any cancer and is one of the most widely published studies in multiple myeloma.

What was the CoMMpass Study?

The MMRF CoMMpass Study represents a cornerstone of the MMRF’s Personalized Medicine Initiative. A longitudinal study, it includes patients with newly diagnosed active multiple myeloma. The goal of this ambitious effort is to map the genomic profile of each patient to clinical outcomes in a ques to develop a more complete understanding of patient responses to treatments. The study is collecting and analyzing tissue samples, clinical data and genetic information from 1,000 newly diagnosed multiple myeloma patients for at least eight years.

Who Funded the MMRF CoMMpass Study?

The CoMMpass Study was made possible by a $40 million investment by the MMRF.

When did the Study commence?

The study started in July of 2011.

How many Patients and Sites are involved in this CoMMpass Study?

As of present, 1,150 patients form 76 sites in the United States, Canada and the European Union are involved.

How is Data generated from the CoMMpass Study accessed?

MMRF makes data available via the Researcher Gateway, an online, open-access portal designed to make key genomic and clinical data available for additional study.

How is such a massive undertaking being supported?

The MMRF CoMMpass Study is supported through a public-private partnership of patient donors and industry partners such as Takeda Oncology, Amgen, Bristol-Myers Squibb, Janssen Pharmaceuticals, Inc. and Janssen Diagnostics. Additional collaborating research partners include the Translational Genomics Research Institute (a City of Hope affiliate)Van Andel Research Institute and GNS Healthcare. See the Partners link

Who is the Principal Investigator for the CoMpass Study?

Sagar Lonial, MD, FACP, Professor and Executive Vice Chair in the Department of Hematology and Medical Oncology and Chief Medical Officer of Winship Cancer Institute

What are some CoMMpass Study highlights to be presented at the forthcoming December 7-10 meetings:

·         Crowd-sourcing effort using CoMMpass data that identified PHF19 as a gene that is strongly associated with disease progression

·         Characterization of new genomic markers that can help predict high-risk disease

·         Discovery of genomic alterations associated with the development of plasma cell leukemia

·         Identification of epigenomic alterations that are prognostic of clinical outcomes

·         Description of genomic differences that may occur for increased incidence of multiple myeloma in African Americans—a separate study on myeloma in African Americans—using examples from their MMRF tissue bank—has helped identify several markers that are significantly associated with myeloma risk in African Americas

About the Multiple Myeloma Research Foundation (MMRF)

A pioneer in precision medicine, the Multiple Myeloma Research Foundation (MMRF) seeks to find a cure for all multiple myeloma patients by relentlessly pursuing innovations that accelerate the development of precision treatments for cancer. Founded in 1998 by Kathy Giusti, a multiple myeloma patient, and her twin sister Karen Andrews as a 501(c)(3) nonprofit organization, the MMRF has created the business model around cancer—from data to analytics to the clinic. The MMRF identifies barriers and then finds the solutions to overcome them, bringing in the best partners and aligning incentives in the industry to drive better outcomes for patients. Since its inception, the organization has collected thousands of samples and tissues, opened nearly 100 trials, helped bring 11 FDA-approved therapies to market, and built CoMMpass, the single largest genomic dataset for any cancer. Today, the MMRF is building on its legacy in genomics and is expanding into immunotherapy, as the combination of these two fields will be critical to making precision medicine possible for all patients. The MMRF has raised nearly $500 million and directs nearly 90% of the total funds to research and related programs. To learn more, visit here.

About the Multiple Myeloma Research Consortium (MMRC)

The Multiple Myeloma Research Consortium (MMRC) is a 509 (a) (3) non-profit organization that integrates leading academic institutions to accelerate drug development in multiple myeloma. It is led from the MMRC offices in Norwalk, Conn., and comprises 25 member institutions: Dana-Farber Cancer Institute, Massachusetts General Hospital Cancer Center, Beth Israel Deaconess, Brigham and Women’s Hospital, Mayo Clinic (Jacksonville, Rochester and Scottsdale), Baylor Charles A. Sammons Cancer Center at Dallas, Barbara Ann Karmanos Cancer Institute, City of Hope, Emory University’s Winship Cancer Institute, Levine Cancer Institute, The John Theurer Cancer Center at Hackensack University Medical Center, Memorial Sloan Kettering, Mount Sinai Icahn School of Medicine, Ohio State University, Sarah Cannon Research Institute, University Health Network (Princess Margaret Hospital), University of Arkansas for Medical Sciences, University of California, San Francisco, University of Chicago, University of Michigan, UT Southwestern, Virginia Cancer Specialists and Washington University in St. Louis.

Call to Action: Interested in learning more? Either attend or find a way to secure presentations from the 61st Annual American Society of Hematology Annual Meeting in Orlando from December 7-10.